MCL1 and osteosarcoma: In this study, by investigating clinical osteosarcoma samples and MDR osteosarcoma cell lines, we show that MiR-26a functions to reverse MDR in human osteosarcoma, wherein the targeted expression of myeloid cell leukemia 1 (MCL1) represents a critical mechanism.